Unexpected Efficacy of Rituximab in Multirelapsing Minimal Change Nephrotic Syndrome in the Adult: First Case Report and Pathophysiological Considerations-Reference-Cited by-同舟云学术

Unexpected Efficacy of Rituximab in Multirelapsing Minimal Change Nephrotic Syndrome in the Adult: First Case Report and Pathophysiological Considerations

Published:2007-01 Issue:1 Volume:49 Page:158-161
ISSN:0272-6386
Container-title:American Journal of Kidney Diseases
language:en
Short-container-title:American Journal of Kidney Diseases

Author:

François Hélène,Daugas Eric,Bensman Albert,Ronco Pierre

Publisher

Elsevier BV

Subject

Nephrology

Reference20 articles.

1. Paraneoplastic glomerulopathies: New insights into an old entity;Ronco;Kidney Int,1999

2. A vascular permeability factor in lymphocyte culture supernants from patients with nephrotic syndrome;Lagrue;Biomedicine,1975

3. CD20: A target antigen for immunotherapy of autoimmune diseases;Perosa;Autoimmun Rev,2005

4. T cells and minimal change disease;Cunard;J Am Soc Nephrol,2002

5. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: A study of 11 cases;Fakhouri;Blood,2005

Cited by 95 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A comparison of two and multiple doses of rituximab in pediatric patients with frequent relapses and steroid- dependent nephrotic syndrome. A single-center study;2024-05-13

2. Impact of Thyroid Cancer Treatment on Renal Function: A Relevant Issue to Be Addressed;Journal of Personalized Medicine;2023-05-11

3. Cost-saving induction immunosuppressive protocol in mild-to-moderate immunological risk renal transplantation;Journal of The Egyptian Society of Nephrology and Transplantation;2023

4. Nephrotoxicity in advanced thyroid cancer treated with tyrosine kinase inhibitors: An update;Critical Reviews in Oncology/Hematology;2021-12

5. Consolidation Treatment and Long-Term Prognosis of Rituximab in Minimal Change Disease and Focal Segmental Glomerular Sclerosis;Drug Design, Development and Therapy;2021-05